Clinical Value of the Sentinel-Node Biopsy in Primary Cutaneous Melanoma
Mené sur 2 001 patients atteints d'un mélanome cutané primitif dont la taille est supérieure ou égale à 1,20 mm, cet essai de phase III évalue l'intérêt d'une biopsie du ganglion sentinelle pour identifier les patients nécessitant rapidement une lymphadénectomie complète et prolonger la survie
In this issue of the Journal, Morton and colleagues1 report the final analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-I), a landmark prospective, randomized clinical trial that caps a 35-year effort to resolve the controversy surrounding the survival benefit of surgical excision of regional lymph nodes as a component of the initial treatment of patients with primary melanoma. Spanning two decades, the MSLT-I also shows the importance of the sentinel-node biopsy for staging and prognostic assessment of melanomas with a thickness of 1.20 mm or more. In the cohort of node-positive patients with intermediate-thickness primary melanomas...
New England Journal of Medicine , éditorial, 2013